Alembic Pharmaceuticals Limited
Symbol: APLLTD.NS
NSE
1003.8
INRMarket price today
33.4305
P/E Ratio
1.2335
PEG Ratio
197.31B
MRK Cap
- 0.01%
DIV Yield
Alembic Pharmaceuticals Limited (APLLTD-NS) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4739.2 | 921.2 | 610.9 | 2850.3 | |||||||||||||
balance-sheet.row.short-term-investments | 4804.2 | 166.4 | 316.2 | 1869.7 | |||||||||||||
balance-sheet.row.net-receivables | 22766.1 | 11291.1 | 11900.1 | 8067.3 | |||||||||||||
balance-sheet.row.inventory | 30145.1 | 14752.7 | 16097 | 14861.5 | |||||||||||||
balance-sheet.row.other-current-assets | 5023.9 | 2135.2 | -0.1 | -0.1 | |||||||||||||
balance-sheet.row.total-current-assets | 62674.3 | 29100.2 | 28607.9 | 25779 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 60805.5 | 29997.3 | 39472.6 | 36480.3 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 172.2 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.long-term-investments | 1769.2 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.tax-assets | 2467.1 | 1230.1 | 58.8 | 1108 | |||||||||||||
balance-sheet.row.other-non-current-assets | -1507.4 | 537.4 | 348.8 | -0.1 | |||||||||||||
balance-sheet.row.total-non-current-assets | 63706.6 | 32728.1 | 42612.4 | 41310.8 | |||||||||||||
balance-sheet.row.other-assets | 0.1 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 126381 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.account-payables | 14417.6 | 6798.1 | 7063.9 | 6687.7 | |||||||||||||
balance-sheet.row.short-term-debt | 14541.5 | 6527.9 | 6449.7 | 3121.8 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 21.5 | |||||||||||||
balance-sheet.row.long-term-debt-total | 1366.4 | 692.3 | 721.4 | 2714.3 | |||||||||||||
Deferred Revenue Non Current | -831.4 | -831.4 | -1976.9 | 855.2 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 831.4 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 1623.4 | 855.4 | -0.1 | 0.2 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3507.8 | 1754.3 | 1679.5 | 3611.7 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 1705.4 | 861.5 | 871.2 | 838.2 | |||||||||||||
balance-sheet.row.total-liab | 37976.2 | 18123.6 | 18844.8 | 16420.1 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 786.2 | 393.1 | 393.1 | 393.1 | |||||||||||||
balance-sheet.row.retained-earnings | 35684.4 | 35684.4 | 25543.9 | 24241 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 133047.2 | 335.4 | 18808.8 | 18513.8 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 7291.8 | 7291.8 | 7629.7 | 8128.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 176809.6 | 43704.7 | 52375.5 | 51276.1 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 214785.8 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | -606.4 | |||||||||||||
balance-sheet.row.total-equity | 176809.6 | 43704.7 | 52375.5 | 50669.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 214785.8 | - | - | - | |||||||||||||
Total Investments | 6407 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.total-debt | 15907.9 | 7220.2 | 7171.1 | 5836.1 | |||||||||||||
balance-sheet.row.net-debt | 15972.9 | 6465.4 | 6560.2 | 4855.5 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 5902.1 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -575.6 | -3673.4 | 2395.4 | |||||||||||||
cash-flows.row.account-receivables | 0 | -2228.8 | -4696.2 | 5109.3 | |||||||||||||
cash-flows.row.inventory | 0 | 1344.4 | -1235.5 | -2986.2 | |||||||||||||
cash-flows.row.account-payables | 0 | -281.7 | 366.7 | 452.7 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 590.5 | 1891.6 | -180.4 | |||||||||||||
cash-flows.row.other-non-cash-items | -5902.1 | 1514.9 | 128 | -3277.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5546.2 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 18.7 | 46.1 | -4.6 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -70 | -1392.9 | -1861 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | -18.7 | 1869.7 | 1861 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 28.2 | 13.8 | -1788.4 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4475.9 | -3719.7 | -8388.1 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -2000 | -3000 | -3792.7 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7340.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -1965.6 | -2751.9 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | 1346 | 3578.4 | -9522.4 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -2619.6 | -2173.5 | -5974.3 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | -9.3 | |||||||||||||
cash-flows.row.net-change-in-cash | 5546.2 | 143.9 | -369.7 | 262.2 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 7314 | 754.8 | 610.9 | 980.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1767.8 | 610.9 | 980.6 | 718.4 | |||||||||||||
cash-flows.row.operating-cash-flow | 5546.2 | 7239.5 | 5523.5 | 14633.8 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.free-cash-flow | 5546.2 | 2805.4 | 1267.1 | 8038.7 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 61181 | 56526.2 | 52317.9 | 52762.2 | |||||||||||||
income-statement-row.row.cost-of-revenue | 17682.1 | 17088.2 | 17231.9 | 15212.7 | |||||||||||||
income-statement-row.row.gross-profit | 43498.9 | 39438 | 35086 | 37549.5 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 4785.4 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.operating-expenses | 37416.9 | 35108.9 | 29160 | 24581.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 55099 | 52197.1 | 46391.9 | 39793.8 | |||||||||||||
income-statement-row.row.interest-income | 0 | 3.3 | 17.3 | 15.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
income-statement-row.row.ebitda-caps | 9020.8 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 6131.3 | 4377.8 | 5874.7 | 12968.4 | |||||||||||||
income-statement-row.row.income-before-tax | 5651.5 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
income-statement-row.row.income-tax-expense | -250.6 | 126.1 | 1044.6 | 2533.2 | |||||||||||||
income-statement-row.row.net-income | 5902.1 | 3419.9 | 5209.4 | 11465 |
Frequently Asked Question
What is Alembic Pharmaceuticals Limited (APLLTD.NS) total assets?
Alembic Pharmaceuticals Limited (APLLTD.NS) total assets is 61828300000.000.
What is enterprise annual revenue?
The annual revenue is 32255000000.000.
What is firm profit margin?
Firm profit margin is 0.711.
What is company free cash flow?
The free cash flow is 28.216.
What is enterprise net profit margin?
The net profit margin is 0.096.
What is firm total revenue?
The total revenue is 0.100.
What is Alembic Pharmaceuticals Limited (APLLTD.NS) net profit (net income)?
The net profit (net income) is 3419900000.000.
What is firm total debt?
The total debt is 7220200000.000.
What is operating expences number?
The operating expences are 35108900000.000.
What is company cash figure?
Enretprise cash is -1478000000.000.